Topic Archives: Sarepta (SRPT)

Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own.] Careful analysis of Ebola sequences in infected Africans confirms this: the entire present Ebola outbreak emerged as a consequence of one boy in Meliandoua, in eastern Guinea, eating a […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • Avatar

    $SRPT #DMD #Exondyl51: FDA can approve, but payers refuse to cover *Analysts track a payer revolt against Sarepta’s...

  • Avatar

    I am talking to day about Sarepta . I am long srpt and I am only a small time trader. About $1000 in Serendipity w...

  • Avatar

    $TRIL - I'm not so sure that is necessarily a vote of confidence that should make us feel good about TRIL. In that arti...

  • DrKSSMDPhD

    Summit is a small UK firm planning to IPO in the US. I was pleasantly surprised by what I found researching this one, th...

  • Avatar

    But there is some bad news for Sarepta (SRPT). Down ~40% in pre-market as FDA is once again requiring additional data o...

  • Avatar

    Hey Anshuman,hope you are doing well. Oncogenix,Prosensa and Sarepta trade on the Nasdaq market.Stock symbols are Oncoge...

  • karmaswimswami

    Sarepta (SRPT) has come up for discussion. This is a gnarly company in gnarly situation going after a gnarly disease (D...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info